Alfuzosin (hydrochloride)

Alfuzosin is a post-synaptic alpha1-adrenergic receptor antagonist commonly used to improve lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). It displays high-affinity with non-selectivity for the three known human alpha1 adrenoceptors (pKi = 8.0, 8.0, and 8.5 for alpha1A, alpha1B, and alpha1D, respectively). Consistent with a role for alpha1 adrenoceptors in mediating contraction of smooth muscle, alfuzosin was first described as having anti-hypertensive effects with peripheral vasodilator properties. In patients with BPH, alfuzosin increases mean urinary flow rate and decreases residual volume. Alfuzosin produces minimal vasodilatory and sexual function side effects.Formal Name: N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide, monohydrochloride. CAS Number: 81403-68-1. Synonyms: SL 77499-10, Uroxatral. Molecular Formula: C19H27N5O4 . HCl. Formula Weight: 425.9. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMSO: 1 mg/ml, Ethanol: 1 mg/ml, PBS (pH 7.2): 1 mg/ml. lambdamax: 246, 331, 344 nm. SMILES: COC1=CC2=C(C(N)=NC(N(C)CCCNC(C3CCCO3)=O)=N2)C=C1OC.Cl. InChi Code: InChI=1S/C19H27N5O4.ClH/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19,/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23),1H. InChi Key: YTNKWDJILNVLGX-UHFFFAOYSA-N.